High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): Implications for heart failure screening programs

Congestive Heart Failure

Volumn 9, Issue 3, 2003, Pages 127-132

  Silver, Marc A ^a   Pisano, Carol ^b  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AGING; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PROTEIN BLOOD LEVEL; PULSE RATE; QUESTIONNAIRE; SCREENING; SYMPTOMATOLOGY; BLOOD; CONGESTIVE HEART FAILURE; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR;

FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RISK ASSESSMENT; RISK FACTORS;

EID: 0042320689     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2003.02589.x     Document Type: Article

References (17)

1. American Heart Association. 2003 Heart and Stroke Statistical Update. Dallas TX: American Heart Association. 2003.
2. McMurray JV, McDonagh TA, Davie AP, et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J. 1998;19:842-846.
3. Levy D, Larson MG, Vassan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1604-1606.
4. Nagagawa O, Ogawa, Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy. Evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.
5. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the International Society for Heart and Lung Transplantation endorsed by the Heart Failure Society of America. Circulation. 2001;104(24):2996-3007.
6. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet. 1998;351:4.
7. Yoshimura M, Yasue H, Okamura K, et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with CHF. Circulation. 1993;87:464-469.
8. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. J Hypertens. 1992;10:907-912.
9. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
10. Luchner A, Burnett JC, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121-1128.
11. Smith H, Pickering RM, Struthers A, et al. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ. 2000;320:906-908.
12. Suzuki T, Yamaoki K, Nakajima O, et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J. 2000;41:205-214.
13. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002;288:1252-1259.
14. McClure SJ, Caruana L, Davie AP, et al. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ. 1998;317:516-519.
15. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351(9095):9-13.
16. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-374.
17. Morrow DA, deLemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation myocardial infarction. J Am Coll Cardiol. 2003;41:1264-1272.